2021
mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent
Sajid A, Matias J, Arora G, Kurokawa C, DePonte K, Tang X, Lynn G, Wu MJ, Pal U, Strank NO, Pardi N, Narasimhan S, Weissman D, Fikrig E. mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent. Science Translational Medicine 2021, 13: eabj9827. PMID: 34788080, DOI: 10.1126/scitranslmed.abj9827.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsGuinea PigsIxodesLiposomesLyme DiseaseMRNA VaccinesNanoparticlesRNA, MessengerVaccinationVaccines, SyntheticConceptsTick-borne infectionsTick-borne infectious diseaseEngorgement weightDisease agentsTicksTick exposureLyme disease agentGuinea pigsTick biteNormal blood mealBlood mealNucleoside-modified mRNALyme diseasePigsLocal rednessMRNA vaccinationMRNA vaccinesBite siteSalivary proteinsPrevents transmissionInfectious diseasesDiseaseVaccineResistanceEffective induction
2005
A recombinant envelope protein vaccine against West Nile virus
Ledizet M, Kar K, Foellmer HG, Wang T, Bushmich SL, Anderson JF, Fikrig E, Koski RA. A recombinant envelope protein vaccine against West Nile virus. Vaccine 2005, 23: 3915-3924. PMID: 15917113, DOI: 10.1016/j.vaccine.2005.03.006.Peer-Reviewed Original Research
2001
Immunization of Mice Against West Nile Virus with Recombinant Envelope Protein
Wang T, Anderson J, Magnarelli L, Wong S, Koski R, Fikrig E. Immunization of Mice Against West Nile Virus with Recombinant Envelope Protein. The Journal Of Immunology 2001, 167: 5273-5277. PMID: 11673542, DOI: 10.4049/jimmunol.167.9.5273.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, ViralImmunizationMiceMice, Inbred C3HRecombinant ProteinsVaccines, SyntheticViral Envelope ProteinsViral VaccinesWest Nile virusConceptsWN virus infectionRecombinant E proteinWest Nile virusVirus infectionC3H/HeN miceE proteinNile virusImmunization of miceRecombinant envelope proteinsPassive administrationCandidate vaccinesHeN miceFatal encephalitisImmunization experimentsImmunoblot assayWN virusInfectionVirus isolatesEnvelope proteinProtein antiserumVirusMiceEncephalitisPatientsImmunization
1998
Vaccination against Lyme Disease with Recombinant Borrelia burgdorferi Outer-Surface Lipoprotein A with Adjuvant
Steere A, Sikand V, Meurice F, Parenti D, Fikrig E, Schoen R, Nowakowski J, Schmid C, Laukamp S, Buscarino C, Krause D. Vaccination against Lyme Disease with Recombinant Borrelia burgdorferi Outer-Surface Lipoprotein A with Adjuvant. New England Journal Of Medicine 1998, 339: 209-215. PMID: 9673298, DOI: 10.1056/nejm199807233390401.Peer-Reviewed Original ResearchConceptsLyme diseaseSerologic testingVaccine efficacyAsymptomatic infectionLipoprotein AInjections of vaccineOuter surface lipoprotein AB. burgdorferi infectionFirst yearPlacebo recipientsPlacebo groupVaccine groupVaccine recipientsStudy entryRandomized trialsSystemic reactionsThird injectionBurgdorferi infectionEffective vaccineSkin lesionsReaction testingVaccineDefinite casesDiseaseInfection
1997
Arthropod- and host-specific gene expression by Borrelia burgdorferi.
de Silva AM, Fikrig E. Arthropod- and host-specific gene expression by Borrelia burgdorferi. Journal Of Clinical Investigation 1997, 99: 377-379. PMID: 9022068, PMCID: PMC507808, DOI: 10.1172/jci119169.Peer-Reviewed Original ResearchAnimalsAntigens, BacterialAntigens, SurfaceBacterial Outer Membrane ProteinsBacterial ProteinsBacterial VaccinesBorrelia burgdorferi GroupClinical Trials, Phase III as TopicDisease ReservoirsDisease VectorsGene Expression Regulation, BacterialHeminHost-Parasite InteractionsHumansIxodesLipoproteinsLyme DiseaseMicePlaguePlasminogen ActivatorsSiphonapteraVaccines, SyntheticYersinia pestisBorrelia burgdorferi enzyme-linked immunosorbent assay for discrimination of OspA vaccination from spirochete infection
Zhang YQ, Mathiesen D, Kolbert CP, Anderson J, Schoen RT, Fikrig E, Persing DH. Borrelia burgdorferi enzyme-linked immunosorbent assay for discrimination of OspA vaccination from spirochete infection. Journal Of Clinical Microbiology 1997, 35: 233-238. PMID: 8968914, PMCID: PMC229545, DOI: 10.1128/jcm.35.1.233-238.1997.Peer-Reviewed Original ResearchConceptsEnzyme-linked immunosorbent assayVaccine failureFalse positivityAntigen preparationsExperimental animalsNatural infectionLyme disease vaccineB. burgdorferiExperimental animal modelsNegative enzyme-linked immunosorbent assayEnzyme-linked immunosorbentWhole-cell sonicateSurface protein AVaccinated subjectsLyme disease casesOuter surface protein AVaccinated personsFalse-positive resultsVaccine trialsOspA vaccinationSpirochete infectionDisease vaccineAnimal modelsHuman Lyme disease casesNegative isolates
1996
Identification of a Borrelia burgdorferi OspA T cell epitope that promotes anti-OspA IgG in mice.
Bockenstedt LK, Fikrig E, Barthold SW, Flavell RA, Kantor FS. Identification of a Borrelia burgdorferi OspA T cell epitope that promotes anti-OspA IgG in mice. The Journal Of Immunology 1996, 157: 5496-502. PMID: 8955199, DOI: 10.4049/jimmunol.157.12.5496.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceAnimalsAntibodies, BacterialAntigens, BacterialAntigens, SurfaceBacterial Outer Membrane ProteinsBacterial VaccinesEpitope MappingFemaleImmunization, PassiveImmunoglobulin GInterleukin-4LipoproteinsLymphocyte ActivationMiceMice, Inbred C3HMolecular Sequence DataPeptidesT-LymphocytesVaccines, SyntheticConceptsT cell epitopesCell epitopesPhase III efficacy studiesTick-borne spirochete Borrelia burgdorferiTreatment-resistant Lyme arthritisT cell responsesSurface protein AB-cell epitopesOuter surface protein ALyme arthritisChallenge infectionIgG productionN-terminal epitopeT cellsMultisystem disorderMurine modelSpirochete Borrelia burgdorferiSubunit vaccineEfficacy studiesCell responsesRecombinant vaccineLyme borreliosisLyme diseaseInfectionBorrelia burgdorferi
1995
Safety and Immunogenicity of an Outer Surface Protein A Vaccine in Subjects with Previous Lyme Disease
Schoen R, Meurice F, Brunet C, Cretella S, Krause D, Craft J, Fikrig E. Safety and Immunogenicity of an Outer Surface Protein A Vaccine in Subjects with Previous Lyme Disease. The Journal Of Infectious Diseases 1995, 172: 1324-1329. PMID: 7594671, DOI: 10.1093/infdis/172.5.1324.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, BacterialAntibody FormationAntigens, SurfaceBacterial Outer Membrane ProteinsBacterial VaccinesBorrelia burgdorferi GroupDose-Response Relationship, DrugEnzyme-Linked Immunosorbent AssayHumansImmunization ScheduleImmunoglobulin GLipoproteinsLyme DiseaseProspective StudiesSafetyVaccines, SyntheticConceptsSide effectsLyme diseaseOspA vaccinePrevious Lyme diseaseThree-dose scheduleLocal side effectsSystemic side effectsLyme vaccineMild arthralgiaVaccine doseThird doseProspective studyOspA antibodiesHealthy volunteersOuter surface proteinsVaccinePatientsDiseaseImmunogenicityDoseMonthsSubjectsSurface proteinsSafetyArthralgiaOral vaccination with an attenuated Salmonella typhimurium strain expressing Borrelia burgdorferi OspA prevents murine Lyme borreliosis
Dunne M, al-Ramadi BK, Barthold SW, Flavell RA, Fikrig E. Oral vaccination with an attenuated Salmonella typhimurium strain expressing Borrelia burgdorferi OspA prevents murine Lyme borreliosis. Infection And Immunity 1995, 63: 1611-1614. PMID: 7890431, PMCID: PMC173199, DOI: 10.1128/iai.63.4.1611-1614.1995.Peer-Reviewed Original ResearchConceptsAnti-OspA antibodyMurine Lyme borreliosisDevelopment of antibodiesMajor outer surface proteinsSalmonella typhimurium strainsOral vaccinationIntradermal challengeMouse modelAttenuated strainOuter surface proteinsHigh titersLyme borreliosisLyme diseaseBorrelia burgdorferiTyphimurium strainsCausative agentDiseaseAntibodiesSurface proteinsSalmonella typhimuriumGavageVaccinationMiceTitersBorreliosis
1993
Protection against antigenically variable Borrelia burgdorferi conferred by recombinant vaccines.
Telford SR, Fikrig E, Barthold SW, Brunet LR, Spielman A, Flavell RA. Protection against antigenically variable Borrelia burgdorferi conferred by recombinant vaccines. Journal Of Experimental Medicine 1993, 178: 755-758. PMID: 8340764, PMCID: PMC2191140, DOI: 10.1084/jem.178.2.755.Peer-Reviewed Original ResearchInability of truncated recombinant Osp A proteins to elicit protective immunity to Borrelia burgdorferi in mice.
Bockenstedt LK, Fikrig E, Barthold SW, Kantor FS, Flavell RA. Inability of truncated recombinant Osp A proteins to elicit protective immunity to Borrelia burgdorferi in mice. The Journal Of Immunology 1993, 151: 900-6. PMID: 8335917, DOI: 10.4049/jimmunol.151.2.900.Peer-Reviewed Original ResearchConceptsA antibodiesOsp AProtective immunityMurine immune responseBorrelia burgdorferiElicit protective immunityGroups of miceDevelopment of antibodiesOuter surface protein A.Vaccine AgsChallenge infectionPassive immunizationActive immunizationImmune responseEtiologic agentIndirect immunofluorescenceLyme diseaseMiceVaccinationA antiseraAntibodiesImmunityConformational epitopesA proteinImmunizationOspA vaccination of mice with established Borrelia burgdorferi infection alters disease but not infection
Fikrig E, Barthold SW, Flavell RA. OspA vaccination of mice with established Borrelia burgdorferi infection alters disease but not infection. Infection And Immunity 1993, 61: 2553-2557. PMID: 8500891, PMCID: PMC280883, DOI: 10.1128/iai.61.6.2553-2557.1993.Peer-Reviewed Original ResearchConceptsBooster injectionComplete Freund's adjuvantVaccination of miceMurine Lyme borreliosisMurine Lyme arthritisFinal booster injectionCommencement of vaccinationNumber of miceSurface protein APostexposure immunizationOuter surface protein APostexposure vaccinationLyme arthritisFreund's adjuvantActive immunizationHeart diseaseC3H miceIncomplete adjuvantVaccinationInfectionLyme borreliosisResolution phaseMiceAdjuvantBorrelia burgdorferiEvasion of protective immunity by Borrelia burgdorferi by truncation of outer surface protein B.
Fikrig E, Tao H, Kantor FS, Barthold SW, Flavell RA. Evasion of protective immunity by Borrelia burgdorferi by truncation of outer surface protein B. Proceedings Of The National Academy Of Sciences Of The United States Of America 1993, 90: 4092-4096. PMID: 7683420, PMCID: PMC46452, DOI: 10.1073/pnas.90.9.4092.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceAnimalsAntibodiesAntibodies, MonoclonalAntigens, BacterialAntigens, SurfaceBacterial Outer Membrane ProteinsBase SequenceBorrelia burgdorferi GroupCloning, MolecularCodonEpitopesEscherichia coliFemaleFluorescent Antibody TechniqueGenes, BacterialHumansLyme DiseaseMiceMice, Inbred C3HPolymerase Chain ReactionRecombinant Fusion ProteinsRecombinant ProteinsRestriction MappingTicksVaccines, SyntheticViral VaccinesConceptsProtective immune responseVaccination immunityProtective immunityProtective antibodiesAntibody responseImmune destructionImmune responseHost defenseOuter surface proteinsLyme diseaseOuter surface protein BBorrelia burgdorferiCausative agentOspBMicePolyclonal antibodiesImmunityAntibodiesPresent studyStrain B31Surface proteinsProtein BPrevious studiesVaccinationOspB.
1992
Long-term protection of mice from Lyme disease by vaccination with OspA
Fikrig E, Barthold SW, Kantor FS, Flavell RA. Long-term protection of mice from Lyme disease by vaccination with OspA. Infection And Immunity 1992, 60: 773-777. PMID: 1541551, PMCID: PMC257553, DOI: 10.1128/iai.60.3.773-777.1992.Peer-Reviewed Original Research
1991
Protection of Mice from Lyme Borreliosis by Oral Vaccination with Escherichia coli Expressing OspA
Fikrig E, Barthold S, Kantor F, Flavell R. Protection of Mice from Lyme Borreliosis by Oral Vaccination with Escherichia coli Expressing OspA. The Journal Of Infectious Diseases 1991, 164: 1224-1227. PMID: 1955724, DOI: 10.1093/infdis/164.6.1224.Peer-Reviewed Original ResearchConceptsOral vaccinationRecombinant OspARecombinant outer surface protein AProtection of miceSerum IgG antibodiesSurface protein ALast boostOuter surface protein AControl miceChallenge infectionIgG antibodiesIntraperitoneal injectionLive Escherichia coliOral preparationsC3H/Day 10Lyme borreliosisVaccinationMiceInfectionBorrelia burgdorferiOspAAntibodiesProtein AGavage
1990
Protection of Mice Against the Lyme Disease Agent by Immunizing with Recombinant OspA
Fikrig E, Barthold S, Kantor F, Flavell R. Protection of Mice Against the Lyme Disease Agent by Immunizing with Recombinant OspA. Science 1990, 250: 553-556. PMID: 2237407, DOI: 10.1126/science.2237407.Peer-Reviewed Original ResearchConceptsRecombinant OspALyme borreliosisC3H/HeJ miceProtection of miceTick-borne illnessB. burgdorferi strain N40Recombinant OspA proteinSurface protein AOuter surface protein AHeJ miceLyme disease agentStrain N40Borrelia burgdorferiB. burgdorferiMiceOspABorreliosisOspA proteinBurgdorferiDisease agentsProtein AVaccineIllnessAntibodies